… phase III study investigated whether continuation maintenance with gemcitabine or switch
maintenance with erlotinib improves clinical outcome compared with observation in patients …

… Five percent of patients discontinued erlotinib due to toxicity. This study showed that
erlotinib … as first-line treatment for pancreatic cancer was assessed in a multicenter, phase III …

… This analysis revealed a median PFS of 10.9 months, which is in line with Phase III studies
of first-line erlotinib in EGFR mutation-positive NSCLC; a median PFS of 13.1 and 11.0 …

… to a phase III study of dacomitinib versus erlotinib in patients with … the PFS in the overall
patient population and in those with wild-… over erlotinib in either of the two patient populations. …

… This study confirms the antitumor activity of erlotinib as first-line therapy in … .21 trial, a phase
III randomized study of erlotinib versus best supportive care in patients with relapsing NSCLC.…

… patients had a partial response and one had a minor response Citation[20]. This study, and
the Phase I study of erlotinib … Phase III studies of combination chemotherapy with erlotinib in …

… Furthermore, most NSCLC patients are diagnosed with stage III or IV disease. Stage IIIA …
Surgery, radiotherapy, and chemotherapy are the primary modalities of stage III NSCLC …

… IUNO was a randomized, double-blind, multicenter, placebo-controlled phase III trial of
maintenance erlotinib versus erlotinib at the time of disease progression in patients with …

… Median survival was 9 months, higher than reported in the phase III studies with docetaxel
(7.5 and 5.7 months in TAX 317 and TAX 320, respectively), pemetrexed (8.3 months) or …

… III study (D0410 study) in patients with unresectable stage III NSCLC following cCRT. The
study preliminary results in 223 patients found a trend in benefit for maintenance erlotinib …